ArticleClinical immunology (Orlando, Fla.)2010
MHC-I-restricted melanoma antigen specific TCR-engineered human CD4+ T cells exhibit multifunctional effector and helper responses, in vitro.
Article in Clinical immunology (Orlando, Fla.), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 46 citations in OpenAlex.
- The ATG8 Family Proteins GABARAP and GABARAPL1 Target Antigen to Dendritic Cells to Prime CD4Cells · 2022Article
- Single-Cell Transcriptomics Reveals Killing Mechanisms of Antitumor Cytotoxic CD4Frontiers in immunology · 2022Article
- Adoptive cell therapy with tumor-specific Th9 cells induces viral mimicry to eliminate antigen-loss-variant tumor cells.Cancer cell · 2021Article
- NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives.Frontiers in immunology · 2018Review
- Recent Advances in Targeting CD8 T-Cell Immunity for More Effective Cancer Immunotherapy.Frontiers in immunology · 2018Review
- Critical biological parameters modulate affinity as a determinant of function in T-cell receptor gene-modified T-cells.Cancer immunology, immunotherapy : CII · 2017Article
- Adaptive Resistance to Cancer Immunotherapy.Advances in experimental medicine and biology · 2017Review
- Human leucocyte antigen class I-redirected anti-tumour CD4Clinical and experimental immunology · 2017Article
- Strategies to genetically engineer T cells for cancer immunotherapy.Cancer immunology, immunotherapy : CII · 2016Review
- Coupling of HIV-1 Antigen to the Selective Autophagy Receptor SQSTM1/p62 Promotes T-Cell-Mediated Immunity.Frontiers in immunology · 2016Article
- PD-1 inhibition and treatment of advanced melanoma-role of pembrolizumab.American journal of cancer research · 2016Review
- T-cell receptor gene therapy--ready to go viral?Molecular oncology · 2015Review
- Trial Watch: Adoptive cell transfer for oncological indications.Oncoimmunology · 2015Review
- Knockdown of T-bet expression in Mart-127-35 -specific T-cell-receptor-engineered human CD4(+) CD25(-) and CD8(+) T cells attenuates effector function.Immunology · 2015Article
- Classification of current anticancer immunotherapies.Oncotarget · 2014Review
- Death receptor-independent activation-induced cell death in human melanoma antigen-specific MHC class I-restricted TCR-engineered CD4 T cells.Journal of immunology (Baltimore, Md. : 1950) · 2013Article
- Role of T cell receptor affinity in the efficacy and specificity of adoptive T cell therapies.Frontiers in immunology · 2013Article
- Abrogation of SRC homology region 2 domain-containing phosphatase 1 in tumor-specific T cells improves efficacy of adoptive immunotherapy by enhancing the effector function and accumulation of short-lived effector T cells in vivo.Journal of immunology (Baltimore, Md. : 1950) · 2012Article
- Trial Watch: Adoptive cell transfer immunotherapy.Oncoimmunology · 2012Article
- Engineering T cells specific for a dominant severe acute respiratory syndrome coronavirus CD8 T cell epitope.Journal of virology · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 4 institutions in 1 country.
Funding
Abstract
MHC class I-restricted human melanoma epitope MART-1(27-35) specific TCR-engineered CD4+CD25- T cells synthesize Th1 type cytokines and exhibit cytolytic effector function upon cognate stimulation. A detailed characterization of such TCR-engineered CD4+CD25- T cells now reveals that they are multifunctional. For example, they undergo multiple rounds of division, synthesize cytokines (IFN-gamma, TNF-alpha, IL-2, and MIP1ss), lyse target cells, and "help" the expansion of the MART-1(27-35) specific CD8+ T cells when stimulated by the MART-1(27-35) peptide pulsed DC. Multiparametric analyses reveal that a single TCR-engineered CD4+ T cell can perform as many as five different functions. Nearly 100% MART-1(27-35) specific TCR expressing CD4+ T cells can be generated through retroviral vector-based transduction and one round of in vitro stimulation by the peptide pulsed DC. MHC class I-restricted tumor epitope specific TCR transduced CD4+ T cells, therefore, could be useful in immunotherapeutic strategies for melanoma or other human malignancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.